
|Videos|February 1, 2018
Dr. Francis Discusses the SOFT Trial for Breast Cancer
Author(s)Prudence Francis, MD
Prudence Francis, MD, Peter MacCallum Cancer Centre, discusses the SOFT trial for patients with breast cancer.
Advertisement
Prudence Francis, MD, Peter MacCallum Cancer Centre, discusses the SOFT trial for patients with breast cancer.
The updated results have a median 8 years of follow-up. There is statistically significant improvement in disease-free survival following this longer follow-up. In the high-risk patients who received chemotherapy, there are overall survival advantages in this group of patients, which needs to be investigated further.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
The OncFive: Top Oncology Articles for the Week of 1/25
3
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
4
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
5



































